The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment

“…Although carboplatin has replaced cisplatin in chemotherapy regimens of other neoplasms (such as ovarian cancers), its success in head and neck cancers has not been clinically proven. Similarly, oxaliplatin has been found eVective for colorectal cancers (Pandor et al 2006) but not for squamous cell carcinomas.…”

Economic Impact of Alternative Adjuvant Chemotherapy Regimens for Stage III Colon Cancer

“…Nevertheless, economic evaluationsperformedintheUnitedKingdomhavefounda favorablecost-effectivenessprofileincomparisonwith5-FU/ LV regimens by reducing the need for expensive palliation for metastatic disease [6]. Although corresponding German dataarenotyetpublished,itmightbereasonabletoconsider FOLFOX-4asthefirstchoiceofchemotherapyaftercurative surgery in stage III colon cancer for medical as well as economic reasons.…”

“…Consideringthehighincidenceofcoloncancer,postoperativechemotherapiesrepresentasignificanteconomicburden fortheGermanhealthcaresystem.Inordertooptimizeresource use, it is very important that physicians learn about the economic consequences of each of the various available regimens.IntheUnitedStatesandtheUnitedKingdom,data fromcost-effectivenessevaluationsofclinicalstudiescomparing different regimens are available, but these data are not easily transferable to the German health care system, since economicpatternssuchasdrugpricing,physicianfees,organization of the office-based sector, and treatment preferences (inpatient/outpatient) vary strongly between countries and over time [6]. Therefore we analyzed treatment-associated resourceuseanddistributionofcost-drivingfactorsofthe5 mostcommonlyusedadjuvantchemotherapyregimensfrom theperspectiveofGermanstatutorysicknessfunds.…”

Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement

“…In terms of reporting, all direct searches, including search strategies should be reported but equally important, in order that the whole process of information acquisition is transparent, is an audit of how all evidence cited in support of a model came to be part of the modelling process. The appendices of two published costeffectiveness models provide examples of how this can be presented [55,56].…”